Darzalex

Drug Overview
Product Profiles
Darzalex : Multiple myeloma
Darzalex : NHL: Mantle cell lymphoma (MCL)

Figure 1: Darzalex for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Darzalex for multiple myeloma
Figure 3: The authors drug assessment summary of Darzalex for multiple myeloma
Figure 4: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Darzalex for mantle cell lymphoma – SWOT analysis

Table 1: Darzalex drug profile
Table 2: Darzalex pivotal trial data in multiple myeloma
Table 3: Darzalex early-phase trial data in multiple myeloma
Table 4: Darzalex Phase III trials in multiple myeloma
Table 5: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 7: Darzalex drug profile
Table 8: Darzalex Phase II trial in mantle cell lymphoma